PRAME 100-108 (HLA-A*02:01) VLDGLDVLL
€105.00*
Description
The PRAME 100-108 peptide with the amino acid sequence VLDGLDVLL is a linear epitope (epitope ID 869501) derived from the Preferentially Expressed Antigen in Melanoma (PRAME, UniProt:P78395). It is used to stimulate human Prame (100-108)-specific CD8+T cells.
PRAME belongs to the cancer/testis antigens in Homo sapiens. This antigen is notably overexpressed in various solid tumors, including melanoma, epithelial ovarian cancer, multiple sarcoma subtypes, and non-small cell lung cancer, while its expression in healthy tissues is mostly restricted to the testes.
The PRAME 100-108 (VLDGLDVLL) epitope is presented by the MHC class I HLA-A*02:01 allele and was initially identified by Kessler et al. in 2001. In their studies, they demonstrated that cytotoxic T lymphocytes, which recognize this high-affinity binding epitope, could specifically target and lyse melanoma, lung, mammary, renal cell and cervical cancer cell lines.
TechData
| Sequence: | VLDGLDVLL |
| Gene: | PRAME |
| Delivery: | 1-3 days |
| C-Terminus: | OH |
| N-Terminus: | H |
| Amount: | 1 mg |
| Counterion: | TFA |
| Protein: | Melanoma antigen preferentially expressed in tumors |
| Species: | Human |
| Allele: | HLA-A*02:01 |
| Application: | Flow Cytometry |
| Indication: | Cancer |
| Purity: | 95% HPLC-MS |
Documents
References
More PRAME peptides
